Literature DB >> 32415512

CircRNA cPWWP2A: an emerging player in diabetes mellitus.

Qijia Yan1, Xiaoyun He1, Gaoyan Kuang2, Chunlin Ou3,4.   

Abstract

Circular RNAs(CircRNAs), a new class of non-coding RNAs, possess significant capabilities of gene regulation and are disrupted in various diseases, including diabetes mellitus (DM). However, the underlying mechanism of CircRNAs in DM and diabetic complications remains illusive. A recent study published by Liu et al. (Proc Natl Acad Sci USA 116:7455-7464, 2019) shown that a novel diabetic retinopathy (DR)-associated CircRNA cPWWP2A, which could act as a competing endogenous RNA interacting with miR-579 to promote the DR-induced retinal vascular dysfunction through up-regulating the expression of Angiopoietin 1, Occludin, and SIRT1. Their findings may provide new insight into the potential use of CircRNA cPWWP2A for the targeted therapy of DR. However, those promising findings may need to be further evaluated detailedly for the following reason. (1) This study doesn't well clarify why the most significantly up-regulated CircRNA mmu _circ_0000254 the fold change of which is 160.581 is excluded,while the cPWWP2A the fold change of which is only 3.487 is chosen. (2) It is difficult to conclude that cPWWP2A competing with miR-579 only by the analysis of colocalization in pericytes.

Entities:  

Keywords:  CeRNA; CircRNA cPWWP2A; Diabetic retinopathy; Therapy

Year:  2020        PMID: 32415512      PMCID: PMC7511486          DOI: 10.1007/s12079-020-00570-7

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  10 in total

Review 1.  Circular RNAs (circRNAs) in cancer.

Authors:  Ruoyu Zhou; Yuwei Wu; Wenxi Wang; Wenjia Su; Yicong Liu; Yumin Wang; Chunmei Fan; Xiaoling Li; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng
Journal:  Cancer Lett       Date:  2018-04-03       Impact factor: 8.679

Review 2.  Circular RNAs function as ceRNAs to regulate and control human cancer progression.

Authors:  Yaxian Zhong; Yajun Du; Xue Yang; Yongzhen Mo; Chunmei Fan; Fang Xiong; Daixi Ren; Xin Ye; Chunwei Li; Yumin Wang; Fang Wei; Can Guo; Xu Wu; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2018-04-07       Impact factor: 27.401

3.  Preventing chronic diseases in China.

Authors:  Longde Wang; Lingzhi Kong; Fan Wu; Yamin Bai; Robert Burton
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

4.  Targeting pericyte-endothelial cell crosstalk by circular RNA-cPWWP2A inhibition aggravates diabetes-induced microvascular dysfunction.

Authors:  Chang Liu; Hui-Min Ge; Bai-Hui Liu; Rui Dong; Kun Shan; Xue Chen; Mu-Di Yao; Xiu-Miao Li; Jin Yao; Rong-Mei Zhou; Shu-Jie Zhang; Qin Jiang; Chen Zhao; Biao Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-26       Impact factor: 11.205

5.  Circular Noncoding RNA HIPK3 Mediates Retinal Vascular Dysfunction in Diabetes Mellitus.

Authors:  Kun Shan; Chang Liu; Bai-Hui Liu; Xue Chen; Rui Dong; Xin Liu; Yang-Yang Zhang; Ban Liu; Shu-Jie Zhang; Jia-Jian Wang; Sheng-Hai Zhang; Ji-Hong Wu; Chen Zhao; Biao Yan
Journal:  Circulation       Date:  2017-08-31       Impact factor: 29.690

Review 6.  Diabetic uropathy.

Authors:  Firouz Daneshgari; Courtenay Moore
Journal:  Semin Nephrol       Date:  2006-03       Impact factor: 5.299

Review 7.  LncRNAs: key players and novel insights into diabetes mellitus.

Authors:  Xiaoyun He; Chunlin Ou; Yanhua Xiao; Qing Han; Hao Li; Suxian Zhou
Journal:  Oncotarget       Date:  2017-08-04

Review 8.  CircRNA: functions and properties of a novel potential biomarker for cancer.

Authors:  Shujuan Meng; Hecheng Zhou; Ziyang Feng; Zihao Xu; Ying Tang; Peiyao Li; Minghua Wu
Journal:  Mol Cancer       Date:  2017-05-23       Impact factor: 27.401

9.  Up-regulation of LINC00467 promotes the tumourigenesis in colorectal cancer.

Authors:  Xiaoyun He; Shen Li; Bingbing Yu; Gaoyan Kuang; Yongrong Wu; Meili Zhang; Yuxiang He; Chunlin Ou; Pengfei Cao
Journal:  J Cancer       Date:  2019-10-19       Impact factor: 4.207

10.  Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer.

Authors:  Chunlin Ou; Zhenqiang Sun; Xiaoyun He; Xiaoling Li; Songqing Fan; Xiang Zheng; Qiu Peng; Guiyuan Li; Xiayu Li; Jian Ma
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

  10 in total
  6 in total

1.  The Construction and Analysis of Immune Infiltration and Competing Endogenous RNA Network in Acute Ischemic Stroke.

Authors:  ZhaoLei Ma; Chun-Feng Liu; Li Zhang; Ning Xiang; Yifan Zhang; Lan Chu
Journal:  Front Aging Neurosci       Date:  2022-05-17       Impact factor: 5.702

2.  circFTO upregulates transforming growth factor-alpha through sponging miR-148a-3p to regulate high glucose-induced ARPE-19 cells injury.

Authors:  Yan Huang; Xueyao Li; Lu Jiang; Chunyan Mo; Miao Luo; Ken Hu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  CircRNA circVEGFC is Highly Expressed in Gestational Diabetes Mellitus (GDM) and It is Correlated with Multiple Adverse Events.

Authors:  Wenjing She; Tao Li; Yan Liu; Xinru Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-01       Impact factor: 3.168

4.  circRNA_0000285 knockdown suppresses viability and promotes apoptosis of cervical cancer cells by sponging microRNA-654-3p.

Authors:  Sisi Zhang; Yingping Xu; Qingyu Zheng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  The Construction and Analysis of Infiltrating Immune Cell and ceRNA Networks in Diabetic Foot Ulcer.

Authors:  Lin Zeng; Pengxiang Zhang; Zebin Fang; Deliang Liu; Huilin Li; Xin Qu; Shufang Chu; Hengxia Zhao; Xuemei Liu; Maosheng Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

Review 6.  Recent Advances in the Potential Use of Circular RNA for the Diagnosis and Treatment of Pancreatic Cancer.

Authors:  Xinzhu Sun; Dongyan Liu; Nan Ge; Jintao Guo; Sheng Wang; Xiang Liu; Guoxin Wang; Siyu Sun
Journal:  Cancer Manag Res       Date:  2021-05-28       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.